Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 19.455 AUD -3.11%
Market Cap: 2.5B AUD

Neuren Pharmaceuticals Ltd
Accounts Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Neuren Pharmaceuticals Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Neuren Pharmaceuticals Ltd
ASX:NEU
Accounts Receivables
AU$20.5m
CAGR 3-Years
81%
CAGR 5-Years
109%
CAGR 10-Years
48%
Recce Pharmaceuticals Ltd
ASX:RCE
Accounts Receivables
AU$435.3k
CAGR 3-Years
34%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Accounts Receivables
AU$164.6m
CAGR 3-Years
-14%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
Accounts Receivables
AU$2.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
76%
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Accounts Receivables
AU$404.3k
CAGR 3-Years
145%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nyrada Inc
ASX:NYR
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Neuren Pharmaceuticals Ltd
Glance View

Market Cap
2.4B AUD
Industry
Pharmaceuticals

Founded in 1993, Neuren Pharmaceuticals Ltd has carved a niche for itself within the biotech industry, focusing primarily on neurological and neurodevelopmental disorders. The company operates at the intriguing intersection of innovation and medicine, where the stakes are high, but so are the potential rewards. Neuren has its headquarters in Australia and has oriented its research towards developing therapies that could change the lives of those affected by conditions like Rett syndrome and Fragile X syndrome. By adopting a strategic approach that combines cutting-edge science with a relentless focus on unmet needs, Neuren positions itself uniquely through its proprietary compounds such as trofinetide and NNZ-2591, which are at the core of its research endeavors. The company's business model hinges on a dual approach: developing its own drugs while simultaneously fostering partnerships with larger pharmaceutical companies to bring these therapies to market. This model allows Neuren to share the substantial costs and risks inherent in drug development while benefiting from the expanse of its partners' distribution networks and market insights. Revenue generation kicks in primarily through milestone payments, royalties, and licensing agreements as these partners help navigate the rigorous phases of clinical trials and regulatory approvals. Financial stability is thus intricately tied to clinical successes and strategic alliances, allowing Neuren to balance the speculative nature of biotech investments with the promise of transformative medical breakthroughs.

NEU Intrinsic Value
HIDDEN
Show

See Also

What is Neuren Pharmaceuticals Ltd's Accounts Receivables?
Accounts Receivables
20.5m AUD

Based on the financial report for Jun 30, 2025, Neuren Pharmaceuticals Ltd's Accounts Receivables amounts to 20.5m AUD.

What is Neuren Pharmaceuticals Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
48%

Over the last year, the Accounts Receivables growth was 38%. The average annual Accounts Receivables growth rates for Neuren Pharmaceuticals Ltd have been 81% over the past three years , 109% over the past five years , and 48% over the past ten years .

Back to Top